loading
Elevation Oncology Inc stock is traded at $0.55, with a volume of 596.28K. It is up +3.71% in the last 24 hours and down -4.27% over the past month. Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
See More
Previous Close:
$0.5315
Open:
$0.531
24h Volume:
596.28K
Relative Volume:
0.82
Market Cap:
$32.17M
Revenue:
-
Net Income/Loss:
$-39.35M
P/E Ratio:
-0.1536
EPS:
-3.58
Net Cash Flow:
$-48.92M
1W Performance:
-17.73%
1M Performance:
-4.27%
6M Performance:
-84.73%
1Y Performance:
+10.24%
1-Day Range:
Value
$0.5221
$0.5565
1-Week Range:
Value
$0.5221
$0.7034
52-Week Range:
Value
$0.4401
$5.8299

Elevation Oncology Inc Stock (ELEV) Company Profile

Name
Name
Elevation Oncology Inc
Name
Phone
(716) 371-1125
Name
Address
101 FEDERAL STREET, BOSTON
Name
Employee
29
Name
Twitter
Name
Next Earnings Date
2024-08-05
Name
Latest SEC Filings
Name
ELEV's Discussions on Twitter

Compare ELEV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ELEV 0.5512 32.17M 0 -39.35M -48.92M -3.58
VRTX 467.50 119.83B 10.63B -479.80M -1.35B 13.33
REGN 761.42 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 564.61 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.58 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.64 24.08B 3.30B -501.07M 1.03B 11.54

Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-23-21 Initiated H.C. Wainwright Buy

Elevation Oncology Inc Stock (ELEV) Latest News

pulisher
Nov 15, 2024

Logos Global Management LP Adjusts Stake in Elevation Oncology I - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

OrbiMed Advisors LLC Increases Stake in Elevation Oncology Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 12, 2024

Elevation Oncology's SWOT analysis: promising ADC stock faces key data readout - Investing.com

Nov 12, 2024
pulisher
Nov 06, 2024

Elevation Oncology’s Q3 2024 Highlights and Financial Report - TipRanks

Nov 06, 2024
pulisher
Nov 06, 2024

Goldman Sachs Group Inc's Strategic Acquisition in Elevation Onc - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

Elevation Oncology's Cancer Drug Shows 43% Response Rate, Secures FDA Fast Track | ELEV Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements - PR Newswire

Nov 06, 2024
pulisher
Nov 05, 2024

Ovarian Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Elevation Oncology Inc - GuruFocus.com

Nov 05, 2024
pulisher
Oct 25, 2024

Alkermes' Q3 Earnings & Revenues Fall Shy Of Estimates, Stock Down - Barchart

Oct 25, 2024
pulisher
Oct 22, 2024

AstraZeneca Receives CHMP's Approval for Wainzua in Europe - Zacks Investment Research

Oct 22, 2024
pulisher
Oct 22, 2024

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies - Yahoo Canada Finance

Oct 22, 2024
pulisher
Oct 19, 2024

SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies - MSN

Oct 19, 2024
pulisher
Oct 17, 2024

GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review - MSN

Oct 17, 2024
pulisher
Oct 16, 2024

Is Elevation Oncology Inc (ELEV) worth investing in despite its overvalued state? - US Post News

Oct 16, 2024
pulisher
Oct 14, 2024

Trading Day Review: Elevation Oncology Inc (ELEV) Gains Momentum, Closing at 0.51 - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

It is Poised to be a Bull Market for Elevation Oncology Inc (ELEV) - SETE News

Oct 14, 2024
pulisher
Oct 11, 2024

Elevation Oncology Inc (ELEV)’s stock price range in the last year - US Post News

Oct 11, 2024
pulisher
Oct 10, 2024

What Makes Elevation Oncology (ELEV) a New Strong Buy Stock - MSN

Oct 10, 2024
pulisher
Oct 09, 2024

Empery Asset Management's Strategic Acquisition in Elevation Oncology - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

In the Green: Elevation Oncology Inc (ELEV) Closes at 0.52, Up/Down -3.69 from Previous Day - The Dwinnex

Oct 09, 2024
pulisher
Oct 04, 2024

Taking on analysts’ expectations and winning: Elevation Oncology Inc (ELEV) - SETE News

Oct 04, 2024
pulisher
Sep 30, 2024

Affimed Appoints New CEO, Shares Fall on Leadership Change - MSN

Sep 30, 2024
pulisher
Sep 30, 2024

Market Momentum Report: Elevation Oncology Inc (ELEV)’s Positive Close at 0.59 - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

Elevation Oncology's SWOT analysis: promising ADC stock faces key data readouts - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Should investors be concerned about Elevation Oncology Inc (ELEV)? - US Post News

Sep 30, 2024
pulisher
Sep 26, 2024

Elevation Oncology Inc (ELEV) Stock: The Story of a 52-Week Stock Range - The InvestChronicle

Sep 26, 2024
pulisher
Sep 24, 2024

Elevance Health Inc [ELV] PERU RAMIRO G sells 753 Shares for $0.4 million - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Check out these key findings about Elevation Oncology Inc (ELEV) - SETE News

Sep 24, 2024
pulisher
Sep 24, 2024

Lombard Odier Asset Management Europe Ltd Invests $2.51 Million in Elevance Health, Inc. (NYSE:ELV) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

FDA grants fast track designation for Elevation Oncology’s EO-3021 - Pharmaceutical Business Review

Sep 24, 2024
pulisher
Sep 24, 2024

Pacer Advisors Inc. Decreases Stock Position in Elevance Health, Inc. (NYSE:ELV) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Distillate Capital Partners LLC Grows Position in Elevance Health, Inc. (NYSE:ELV) - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

Study Underscores Importance of Medicaid Coverage for Pregnant Women - Healthcare Innovation

Sep 23, 2024
pulisher
Sep 23, 2024

Elevai Labs shares tumble on pricing of new stock offering - The Business Journals

Sep 23, 2024
pulisher
Sep 23, 2024

Elevance Health, Inc. (NYSE:ELV) Position Boosted by Magnetar Financial LLC - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Decoding Elevance Health's Options Activity: What's the Big Picture? - Benzinga

Sep 23, 2024
pulisher
Sep 23, 2024

ELAB’s price-to-free cash flow ratio: What it means for investors - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Ratios in Focus: Analyzing Elevation Oncology Inc (ELEV)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Why Elevai Labs (ELAB) Stock Is Down 60% Today - Benzinga

Sep 23, 2024
pulisher
Sep 23, 2024

Investing in Elevation Oncology Inc (ELEV) might be a great opportunity, but the stock is a bit undervalued - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Baltic Fintech Eleving To Raise Up To €30M In IPO - Law360

Sep 23, 2024
pulisher
Sep 23, 2024

FDA grants fast track to Elevation Oncology's cancer drug - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

Ensign Peak Advisors Inc Acquires 2,862 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering - GlobeNewswire

Sep 23, 2024
pulisher
Sep 23, 2024

Elevation Oncology Gets FDA Fast-Track Designation for EO-3021 - MarketWatch

Sep 23, 2024
pulisher
Sep 23, 2024

Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 - StockTitan

Sep 23, 2024
pulisher
Sep 23, 2024

Eleving Group Targets $34 Million From Initial Public Offering - MarketWatch

Sep 23, 2024
pulisher
Sep 22, 2024

Fidelis Capital Partners LLC Acquires 1,168 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

1832 Asset Management L.P. Sells 5,622 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

Frank Rimerman Advisors LLC Raises Stock Position in Elevance Health, Inc. (NYSE:ELV) - Defense World

Sep 22, 2024

Elevation Oncology Inc Stock (ELEV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.25
price down icon 0.96%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):